In relation to this article, abdm just posted this on the OBJ...

In relation to this article, abdm just posted this on the OBJ thread:

"The following criteria is noted on Bioscience Managers website:

Investment Criteria

The IB Asia Pacific Healthcare Fund II Seeks to Invest in;

Entities in the Healthcare & Medical Science sector:
•The Fund will assess companies in the fields of Heathcare, Life Science, Hospital Serivices, Contract Research Organistions / Serivice Providers and other health related auxillary entities.

Entities in the Asia Pacific Region:
•The Fund would assess companies domicilied in, or have a tangible link with Australia, New Zealand, Singapore, Mainland China, India, Indonesia, Vietnam, Malaysia, Thailand, the Republic of Korea, Hong Kong, Taiwan and Japan.

Proprietary technologies with international relevance:
•The Fund seeks globally relevent business and technologies, that have broader application than its domestic market,
•The Fund will consider investment into entities that seek to expand into new jurisdictions,
•The asset will usually be globally relevent.

Identified exit opportunities:
•The ability for Trade sale, Merger or Quotation of the entities securities on a globally relevent stock exchange must be present,
•An exit horizon of 3-5 years.

A strong IP position:
•All intellectual property must be relevent and unencumbered,
•Patents should be validated.

Programmes in clinical development or generating revenue:
•The technology or assets must be in human clinical trials or in the revenue-growth phase,
•Preclinical evaluation and blueprinting should be completed.

Intersuisse Bioscience Managers"